PATIENT INFORMATION

The clinical study phase IIb with LT-02 in patients who suffer from active ulcerative colitis was successfully completed.
This phase IIb study was performed with support from Dr. Falk Pharma GmbH, Freiburg, Germany.

Following a co-development and option-agreement Dr. Falk will assume full responsibility for the further development and commercialization of LT-02 in Europe.

The pivotal Phase III clinical trial in ulcerative colitis has started in Europe in June of 2014

For further information please contact:

DR. FALK PHARMA GmbH
Leinenweberstr. 5
D-79108 Freiburg
Postfach 6529
D-79041 Freiburg
Germany

Tel.:
Fax:
0049 / 761 / 1514-0
0049 / 761 / 1514-321